Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from construct pragmatic trial

HIGHLIGHTS

  • who: Mohammed Fasihul Alam from the (UNIVERSITY) have published the research work: Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial, in the Journal: (JOURNAL)
  • what: The study aimed to perform decision analytic model-based longterm cost-utility analysis (CUA) of infliximab versus ciclosporin for steroid-resistant ASUC investigated in CONSTRUCT pragmatic trial. Details on NHS resource uses, how these were captured and their costs (in 2012-13 prices in Great Britain Pound (GBP) sterling) were reported in the CONSTRUCT main report . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?